1. WHO. Coronavirus disease 2019 (COVID-19) Situation. Report — 51. URL: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10 (accessed 13.06.2020).
2. Wiersinga W.J., Rhodes A., Cheng A.C., et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): review. JAMA. 2020; ePub 10.07.2020: E1–E13. https://doi.org/10.1001/jama.2020.12839 PMID: 32648899
3. Hoffman M., Kleine-Weber H., Schroeder S., et al. SARS-CoV-2 entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181(2): 271–80.e8. https://doi.org/10.1016/j.cell.2020.02.052 PMID: 32142651
4. Sungnak W., Huang N., Becavin C., et al. SARS-CoV-2entryfactors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020; 26(5): 681–7. https://doi.org/10.1038/s41591-020-0868-6 PMID: 32327758
5. Clerkin K.J., Fried J.A., Raikhelkar J., et al. Coronavirus disease 2019 (COVID-2019) and cardiovascular disease. Circulation. 2020; 141(20): 1648–55. https://doi.org/10.1161/CIRCULATIONAHA.120.046941 PMID:32200663
6. Goshua G., Pine A.B., Meizlish M.L., et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Hematol. 2020; 7(8): e575–82. https://doi.org/10.1016/S2352-3026(20)30216-7 PMID: 32619411
7. Varga Z., Flammer A.J., Staiger P., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395(10234): 1417–18. https://doi.org/10.1016/S0140-6736(20)30937-5 PMID:32325026
8. Xu Z., Shi L., Wang Y., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4): 420–2. https://doi.org/10.1016/S2213-2600(20)30076-X PMID:32085846
9. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020; 395(10223): 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5 PMID: 31986264
10. Li L.Q., Huang T., Wang Y.Q., et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J.MedVirol. 2020; 92(6): 577–83. https://doi.org/10.1002/jmv.25757 PMID: 32162702
11. Zhou D., Dai S.M., Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicbob Chemother. 2020; 75(7): 1667–70. ttps://doi.org/10.1093/jac/dkaa114 PMID: 32196083
12. Wang M., Cao R., Zhang L., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269–71. https://doi.org/10.1038/s41422-020-0282-0 PMID: 32020029
13. Gautret P., Lagier J.C., Parola P., et al. Hydroxychloroquine and Azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1): 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949 PMID: 32205204
14. Ревматология. Фармакотерапия без ошибок: руководство для врачей. Под ред. В.И. Мазурова, О.М. Лесняк. М.: Е-ното; 2017. 109 с.
15. Российские клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа; 2020. 448 с.
16. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)», версия 5, утверждены Министерством здравоохранения РФ 08.04.2020. URL: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/049/951/original/09042020_%D0%9C%D0%A0_COVID-19_v5.pdf (дата обращения: 25.04.2020)
17. Cortegiani A., Ingoglia G., Ippolito M., et al. A systemic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020; 57: 279–83. https://doi.org/10.1016/j.jcrc.2020.03.005 PMID: 32173110
18. Gao J., Tian Z., Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19-associated pneumonia in clinical studies. Biosci Trends. 2020; 14(1): 72–3. https://doi.org/10.5582/bst.2020.01047 PMID: 32074550
19. Delang L., Neyts J. Medical treatment options for COVID-19. European Heart Journal: Acute Cardivascular Care. 2020; 9(3): 209–14. https://doi.org/10.1177/2048872620922790 PMID:32363880
20. Rosenberg E.S., Dufort E.M., Udo T., et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020; 323(24): 2493–502. https://doi.org/10.1001/jama.2020.8630 PMID: 32392282
21. Nguyen L.S., Dolladille C., Drici M.-D., et al. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization Pharmacovigilance Database. Circulation. 2020; 142(3): 303–5.https://doi.org/10.1161/CIRCULATIONAHA.120.048238 PMID: 32442023
22. Richardson S., Hirsch J.S., Narasimhan M., et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020; 323(20): 2052–59. https://doi.org/10.1001/jama.2020.6775 PMID: 32320003
23. Docherty A.B., Harrison E.M., Green C.A., et al. ISARIC4C investigators. Features of 20133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterization Protocol: prospective observational cohort study. BMJ. 2020; 369: m1985. https://doi.org/10.1136/bmj.m1985 PMID: 32444460
24. Garg S., Kim L., Whitaker M., et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 — COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (15): 458–64. https://doi.org/10.15585/mmwr.mm6915e3 PMID: 32298251
25. Grasselli G., Zangrillo A., Zanella A., et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323(16): 1574–81. https://doi.org/10.1001/jama.2020.5394 PMID: 32250385
26. Long B., Brady W.J., Koyfman A., et al. Cardiovascular complications in COVID-19. Am J Emerg Med.2020; 38(7): 1504–7. https://doi.org/10.1016/j.ajem.2020.04.048 PMID:32317203
27. Guzik T.J., Mohiddin S.A., Dimarco A., et al. COVID-19 and cardiovascular system: implications for risk assessment, diagnosis and treatment options. Cardiovasс Res. 2020; 116(10): 1666–87. https://doi.org/10.1093/cvr/cvaa106 PMID: 32352535
28. Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. 2020; 20(6): 630–31. https://doi.org/10.1016/S1473-3099(20)30257-7 PMID: 32240633
29. Yang L., Tu L. Implication of gastrointestinal manifestations of COVID-19. Lancet Gastroenterol Hepatol. 2020 Jul; 5(7): 629–30. https://doi.org/10.1016/S2468-1253(20)30132-1.PMID: 32405602